Time to fix pharma’s outdated business modelThe disconnect between payers and pharma companies is just one symptom of pharma’s outdated business model, according to Share XTime to fix pharma’s outdated business modelhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/janssen-kris-sterkens-pharma-business-model/
Bringing gene therapies to marketDoug Danison, vice-president, head of access, value and evidence strategy at bluebird bio, a gene therapy company, looks Share XBringing gene therapies to markethttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/bluebird-bio-gene-therapies-market/
NHS England gets commercialNHS England is no longer the new kid on the block, taking up its role in 2013. In Share XNHS England gets commercialhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/nhs-england-commercial-framework-vpas/
Under the skin of innovationLEO’s Innovation Lab is working at arm’s length from the main company to encourage original thinking and develop Share XUnder the skin of innovationhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/leo-innovation-lab-john-zibert-digital/
How digital could transform stakeholder engagementDigital may be upending every aspect of the pharma industry, but many would assume that engagement activities like Share XHow digital could transform stakeholder engagementhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/impetus-digital-stakeholder-engagement/
The future of R&D innovationAlexander Gray and Mike Rea from IDEA Pharma explain why the current pharma R&D model is broken, and Share XThe future of R&D innovationhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/idea-pharma-future-research-innovation/
US healthcare reform scenarios and their impact on the systemIn an effort to control healthcare costs, provide healthcare to the uninsured and underinsured, and improve health outcomes, Share XUS healthcare reform scenarios and their impact on the systemhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/icon-us-healthcare-reform-scenarios/
China in the fast laneBrett Gardiner and Boon Yap from Research Partnership discuss access opportunities for novel therapies in the world’s hottest Share XChina in the fast lanehttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/research-partnership-pharma-market-access-china/
Developing with start-up DNAAs head of digital at Sandoz, Andre Heeg is at the forefront of transformation both within his company Share XDeveloping with start-up DNAhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/sandoz-andre-heeg-digital-startups/
